Can a stronger eye drop dose shield the retina after cataract surgery?

NCT ID NCT07749027

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial tests whether a higher dose of nepafenac eye drops is better than a lower dose at preventing macular edema—a swelling of the central retina—after cataract surgery. Adults aged 18 to 60 scheduled for cataract surgery will receive either a 0.3% solution once daily or a 0.1% solution three times daily, starting the day before surgery and continuing for 60 days. The study measures changes in central macular thickness and treatment compliance to see which regimen offers better protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nepafenac sodium ophthalmic suspension (0.1% or 0.3%)
What this could lead to
If the high-dose regimen works better, it could offer a more effective way to prevent macular edema, a common complication after cataract surgery, potentially improving visual recovery for many patients.
What could go wrong
This is a single-center study with a modest sample size, and results may not apply broadly. Also, higher doses may increase the risk of eye irritation or other side effects, and the benefit over the low dose might be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bahawal Victoria Hospital/Quaid-e-Azam Medical College

    Bahawalpur, Punjab Province, 63100, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.